Imaging chemokine receptor dimerization with firefly luciferase complementation

Seven‐transmembrane (G‐protein coupled) receptors are key regulators of normal physiology and a large number of diseases, and this family of receptors is the target for almost half of all drugs. Cell culture models suggest that homodimerization and heterodimerization of 7‐transmembrane receptors regulate processes including specificity of ligand binding and activation of downstream signaling pathways, making receptor dimerization a critical determinant of receptor biology and a promising new therapeutic target. To monitor receptor dimerization in cell‐based assays and living animals, we developed a protein fragment complementation assay based on firefly luciferase to investigate dimerization of chemokine receptors CXCR4 and CXCR7, two 7‐transmembrane receptors with central functions in normal development, cancer, and other diseases. Treatment with chemokine ligands and pharmacologic agents produced time‐ and dose‐dependent changes in reporter signal. Chemokines regulated reporter bioluminescence for CXCR4 or CXCR7 homodimers without affecting signals from receptor heterodimers. In a tumor xenograft model of breast cancer, we used bioluminescence imaging to measure changes in receptor homodimerization in response to pharmacologic agents. This technology should be valuable for analyzing function and therapeutic modulation of receptor dimerization in intact cells and living mice.— Luker, K. E., Gupta, M., Luker, G. D. Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J. 23, 823–834 (2009)

[1]  Erez Raz,et al.  Control of Chemokine-Guided Cell Migration by Ligand Sequestration , 2008, Cell.

[2]  Robert J. Lefkowitz,et al.  Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases , 2012 .

[3]  P. Toth,et al.  Regulation of CXCR4 Receptor Dimerization by the Chemokine SDF-1α and the HIV-1 Coat Protein gp120: A Fluorescence Resonance Energy Transfer (FRET) Study , 2004, Journal of Pharmacology and Experimental Therapeutics.

[4]  Gary D. Luker,et al.  Noninvasive Bioluminescence Imaging of Herpes Simplex Virus Type 1 Infection and Therapy in Living Mice , 2002, Journal of Virology.

[5]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[6]  David Baltimore,et al.  Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors , 2002, Science.

[7]  Lakshmi A. Devi,et al.  Targeting opioid receptor heterodimers: Strategies for screening and drug development , 2006, The AAPS Journal.

[8]  Andrea Iaboni,et al.  A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer , 2006, Nature Methods.

[9]  Gregory J Babcock,et al.  Ligand-independent Dimerization of CXCR4, a Principal HIV-1 Coreceptor* , 2003, The Journal of Biological Chemistry.

[10]  H. Piwnica-Worms,et al.  Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Chih-Hung Lee,et al.  Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases , 2006, Molecular Cancer Therapeutics.

[12]  Kevin Wei,et al.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development , 2006, The Journal of experimental medicine.

[13]  D. Piwnica-Worms,et al.  Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. , 1997, Biochemistry.

[14]  M. Bouvier,et al.  Roles of G‐protein‐coupled receptor dimerization , 2004, EMBO reports.

[15]  C. Combs,et al.  Dimerization of CXCR4 in living malignant cells: control of cell migration by a synthetic peptide that reduces homologous CXCR4 interactions , 2006, Molecular Cancer Therapeutics.

[16]  F. Baleux,et al.  enhanced chemotaxis to CXCL12 in WHIM syndrome CXCR4 dimerization and ²-arrestinmediated signaling account for the , 2009 .

[17]  M. Parmentier,et al.  Allosteric properties of G protein-coupled receptor oligomers. , 2007, Pharmacology & therapeutics.

[18]  Kathryn E Luker,et al.  Functions of CXCL12 and CXCR4 in breast cancer. , 2006, Cancer letters.

[19]  J. Broach,et al.  A Point Mutation That Confers Constitutive Activity to CXCR4 Reveals That T140 Is an Inverse Agonist and That AMD3100 and ALX40-4C Are Weak Partial Agonists* , 2002, The Journal of Biological Chemistry.

[20]  R. Alon,et al.  A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12‐triggered integrin activation but not in chemokine‐triggered motility of human T lymphocytes and CD34+ cells , 2008, Journal of leukocyte biology.

[21]  G. Downey,et al.  L-selectin stimulation enhances functional expression of surface CXCR4 in lymphocytes: implications for cellular activation during adhesion and migration. , 2003, Blood.

[22]  Abhijit De,et al.  Noninvasive imaging of protein‐protein interactions from live cells and living subjects using bioluminescence resonance energy transfer , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  M. Thelen,et al.  The Chemokine SDF-1/CXCL12 Binds to and Signals through the Orphan Receptor RDC1 in T Lymphocytes* , 2005, Journal of Biological Chemistry.

[24]  E. Clercq.  The bicyclam AMD3100 story , 2003, Nature Reviews Drug Discovery.

[25]  Richard P. Harvey,et al.  Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7 , 2007, Proceedings of the National Academy of Sciences.

[26]  F. Baleux,et al.  CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. , 2008, Blood.

[27]  D. Piwnica-Worms,et al.  CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004, Cancer Research.

[28]  M. Akamatsu,et al.  Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. , 2003, Organic & biomolecular chemistry.

[29]  Michel Bouvier,et al.  Bioluminescence Resonance Energy Transfer Reveals Ligand-induced Conformational Changes in CXCR4 Homo- and Heterodimers* , 2005, Journal of Biological Chemistry.

[30]  K. Pienta,et al.  The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer* , 2008, Journal of Biological Chemistry.

[31]  Alnawaz Rehemtulla,et al.  CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature , 2007, Proceedings of the National Academy of Sciences.

[32]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[33]  M. Burdick,et al.  The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. , 2003, American journal of respiratory and critical care medicine.

[34]  Marc Parmentier,et al.  Allosteric Transinhibition by Specific Antagonists in CCR2/CXCR4 Heterodimers* , 2007, Journal of Biological Chemistry.

[35]  Mudit Gupta,et al.  Imaging CXCR4 signaling with firefly luciferase complementation. , 2008, Analytical chemistry.

[36]  J. Heuser,et al.  Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation , 1989, The Journal of cell biology.